Table 3.

Univariate analysis for predictors of clinically inactive disease of 6 months. Values are median (IQR) unless otherwise specified.

Anakinra Study	Inactive Disease	Active Disease	p
Patients, n (%)	14 (56)	11 (44)
Female, n (%)	6 (43)	6 (55)	1.0^**
Age at disease onset, yrs	7.4 (4.8–9.7)	3.3 (2.0–6.2)	0.090^{^†}
Age of treatment start, yrs	7.9 (4.9–9.9)	6.2 (4.4–12.5)	0.891^{^†}
MAS at disease onset, n (%)	4 (29)	3 (27)	1.0^**
Time from onset to receiving anakinra, mos	1.9 (0.8–5.4)	24.5 (6.2–58.4)	0.003^{^†}^*
Concomitant glucocorticoids, n (%)	6 (43)	8 (73)	0.227^**
Concomitant DMARD, n (%)	3 (21)	6 (55)	0.115^**
Fever, > 38.0°C, n (%)	14 (100)	9 (82)	0.183^**
Rash, n (%)	13 (93)	6 (55)	0.056^**
No. active joints	3 (2–4.5)	4 (2–12)	0.160^{^†}
ESR, mm/h	76 (65.3–88.8)	90 (66.5–106.5)	0.460^{^†}
CRP, mg/dl	13.4 (9.7–15.7)	13.6 (6.6–18.4)	0.870^{^†}
Ferritin, ng/ml	1506 (407–3520)	360 (177–1915)	0.079^{^†}
WBC count, × mm³	15.5 (8.6–23.3)	12.8 (8.4–18.7)	0.298^{^†}
Neutrophil count, × mm³	12.6 (6.4–16.5)	7.4 (5.9–14.4)	0.324^{^†}
Hemoglobin, g/dl	10.6 (9.4–11.1)	10.8 (10–11.5)	0.493^{^†}
Platelet count, × mm³	416.5 (385.3–638.5)	427 (378.5–590)	0.827^{^†}

↵* p < 0.05.
↵** Fisher’s exact test.
↵† Mann-Whitney U test. IQR: interquartile range; MAS: macrophage activation syndrome; DMARD: disease-modifying antirheumatic drugs; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; WBC: white blood cell.